Premium
Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low‐risk gestational trophoblastic neoplasia
Author(s) -
GILANI Mitra Modares,
YARANDI Fariba,
EFTEKHAR Zahra,
HANJANI Parviz
Publication year - 2005
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.2005.00366.x
Subject(s) - dactinomycin , gestational trophoblastic neoplasia , methotrexate , medicine , chemotherapy , pulse (music) , surgery , biology , cycloheximide , microbiology and biotechnology , protein biosynthesis , engineering , detector , electrical engineering
Methotrexate and dactinomycin are efficient drugs in the treatment of patients with low‐risk gestational trophoblastic neoplasia (LRGTN). To compare the effectiveness of these two drugs in LRGTN, 46 patients were randomised to receive weekly intramuscular methotrexate at 30 mg/m 2 ( n = 28) or intravenous dactinomycin at 1.25 mg/m 2 every 2 weeks ( n = 18). Fourteen patients (50%) in the methotrexate group and 16 patients (89%) in the dactinomycin group achieved complete response. Greater patient convenience and a lower number of required visits make dactinomycin superior to other alternatives.